Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial

[1]  A. Ohtsu,et al.  Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407) , 2016, Gastric Cancer.

[2]  M. Terashima,et al.  Staging Laparoscopy for Patients with cM0, Type 4, and Large Type 3 Gastric Cancer , 2015, World Journal of Surgery.

[3]  Y. Kodera,et al.  A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106) , 2015, Gastric Cancer.

[4]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[5]  C. D'aniello,et al.  The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows , 2015, Anti-cancer drugs.

[6]  A. Ejaz,et al.  Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. , 2014, Journal of the American College of Surgeons.

[7]  Kazuhiro Yoshida,et al.  Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. , 2014, The Lancet. Oncology.

[8]  F. Roviello,et al.  Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  A. Nashimoto,et al.  Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210) , 2013, Journal of surgical oncology.

[10]  Y. Kodera.  GASTRIC CANCER WITH MINIMAL PERITONEAL METASTASIS: IS THIS A SIGN TO GIVE UP OR TO TREAT MORE AGGRESSIVELY? , 2013, Nagoya journal of medical science.

[11]  A. Nashimoto,et al.  Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2 , 2011, Gastric Cancer.

[12]  Y. Kodera,et al.  A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). , 2011, Japanese journal of clinical oncology.

[13]  Y. Kodera,et al.  A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  H. Baba,et al.  Extensive Intraoperative Peritoneal Lavage as a Standard Prophylactic Strategy for Peritoneal Recurrence in Patients with Gastric Carcinoma , 2009, Annals of surgery.

[15]  H. Nagawa,et al.  Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  H. Nagawa,et al.  Phase I Pharmacokinetic Study of Weekly Intravenous and Intraperitoneal Paclitaxel Combined with S-1 for Advanced Gastric Cancer , 2009, Oncology.

[17]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[18]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[19]  Y. Kodera,et al.  A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). , 2007, Anticancer research.

[20]  Y. Kodera,et al.  Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. , 2007, Hepato-gastroenterology.

[21]  R. Hariprasad,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[22]  J. Sakamoto,et al.  Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. , 2006, World journal of gastroenterology.

[23]  Joan L. Walker,et al.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Tokunaga,et al.  Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer , 2000, The British journal of surgery.

[25]  S. Noh,et al.  Recurrence following curative resection for gastric carcinoma , 2000, The British journal of surgery.

[26]  M Markman,et al.  Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Dottino,et al.  Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: assessment of acute postoperative morbidity. , 1993, Gynecologic oncology.

[28]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[29]  H. Shiozaki,et al.  Safety of intraperitoneal administration of paclitaxel after gastrectomy with en‐bloc D2 Lymph node dissection , 2012, Journal of surgical oncology.

[30]  J. Sakamoto,et al.  A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer , 2006, Gastric Cancer.